Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu


Welcome to the Multiple Sclerosis Discovery Forum

An online community and information portal that aims to inspire connections and clinical advances



Become a Member

News & Future Directions

News Briefs | 18 Apr 2014

MS Research Roundup: April 18, 2014

Progress Toward New MS Clinical Trial Outcomes; Adaptive Design Evolves; A Call for Fundamental Neuroscience Research; MS Miracle Cures

Items of interest to multiple sclerosis researchers from around the Web...
New Findings | 17 Apr 2014

Myelin and Axons Don’t Form a Perfect, Uniform Union

New findings from mice may rewrite our understanding of just about everything myelin-related. Outside experts describe the study as “landmark,” “novel,” “unexpected,” “new,” “important,” “surprising,” “stunning,” and “provocative.”

Myelin, the fatty insulation that boosts nerve signal conduction, might not be the ubiquitous...
Blogs | 17 Apr 2014

Heartbleed Bug

Please consider changing your MSDF password.

Regarding the Heartbleed Bug: Pantheon, our web host, patched their platform on Monday, April 7,

News Briefs | 15 Apr 2014

Antibody Testing Affects MS Therapy Management

In a randomized trial, access to antibody testing affected MS management. Serum binding antibodies predicted positivity to neutralizing antibodies in patients on high-dose interferon.

Access to antibody testing affected management in persons with multiple sclerosis, according to findings from...
New Findings | 14 Apr 2014

Explaining Fingolimod’s Fatal Flaw

The unphosphorylated, “inactive” version of fingolimod may be responsible for one of the drug’s most serious downsides: susceptibility to viral infections

Because it’s a pill, fingolimod spares MS patients from shots, but it also boosts the risk of...

Research Resources

Tools that will help investigators conceive and perform experimental work:

We've recently added five new trials, updated information on three other trials, and added 27 other pieces of information. The drugs with important additions and changes are alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon β-1a, interferon β-1b, and natalizumab.
We've also added GNbAC1 as a new entry, which contains information on two trials and 16 other pieces of information.

  • Tissue Repositories lists features of the world's tissue repositories and brain banks, including rules of engagement and contact information
  • MSGene provides a comprehensive, unbiased and regularly updated collection of genetic association studies performed on multiple sclerosis phenotypes
  • Animal Models summarizes the promises and pitfalls of animal models used in MS research

  • Clinical Trials lists sources of information about MS clinical trials

Professional Resources

Papers of the Week


Discussions | 22 Oct 2013

Evoked potential test

I'm interested in everything related to Evoked Potential  testing

Recent Comments

New Findings | 17 Apr 2014
Another key question : How does this fit with the...
News Briefs | 16 Apr 2014
As a national speaker for many years for all the...
News Briefs | 16 Apr 2014
I was not involved in this study, and I do not...

MSDF Tweets

NYAS T Cell Meeting

In the News
Read Science Translational Medicine's article about MS Discovery Forum